tirzepatide fda changes backtracks over Eli Lilly weight-loss drug shortage FDA ban on compounded tirzepatide:

Repeatedly missing doses by several days can create fluctuations in medication levels that may reduce your treatment's overall effectiveness

Swallowing after dissolution poses no risk to the medications efficacy, as absorption has already occurred

Real-world data show that the GLP-1 receptor agonists semaglutide and tirzepatide not only manage blood sugar and weight but also mirror their heart-protective effects from clinical trials in everyday patients

Your provider makes the call for your specific protocol

you should talk with your clinician about any symptoms you notice

Accessed 22/2/2025 Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB